



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

30th January, 2026

Corporate Relationship Department
M/s. BSE Limited
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Bandra (E), Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that in accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, NATCO Pharma Asia Pte. Ltd., a wholly-owned subsidiary ("WOS") of NATCO Pharma Limited ("NATCO") incorporated in Singapore, has acquired 49% of shareholding in PT NATCO Lotus Farma from PT Lotus Farma Indonesia.

NATCO already owns 51% of PT NATCO Lotus Farma. Post this acquisition, NATCO alongwith its WOS wholly-owns 100% of PT NATCO Lotus Farma.

The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid investment is enclosed as Annexure – I.

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: As above



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Annexure – I

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Details of Investment
A	Name of the target entity, details in brief such as size, turnover etc.	1) Name of the target entity PT NATCO Lotus Farma 2) Details in brief such as size, turnover etc. Turnover of last 3 years: YTD Sep 2025: IDR 5,073 million (~₹ 2.7 crores) April - March 2025: IDR 3,324 million (~₹ 1.6 crores) April - March 2024: NIL April - March 2023: NIL
B	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	No
C	Industry to which the entity being acquired belongs	Pharmaceuticals
D	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To wholly own the Indonesian subsidiary
E	Brief details of any governmental or regulatory approvals required for the acquisition	NIL
F	Indicative time period for completion of the acquisition;	Already completed
G	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

H	Cost of acquisition or the price at which the shares are acquired	IDR 14,075,400,000 (~₹7.7 crores) At par/nominal per share value of IDR 100,000
I	Percentage of shareholding / control acquired and / or number of shares acquired	49% Post this acquisition, NATCO alongwith its WOS wholly-owns PT NATCO Lotus Farma
J	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Brief background: 1. Line of business: Pharmaceuticals 2. Date of incorporation: August 28, 2023 3. Turnover of last 3 years: YTD Sep 2025: IDR 5,073 million (~₹ 2.7 crores) April - March 2025: IDR 3,324 million (~₹ 1.6 crores) April - March 2024: NIL April - March 2023: NIL 4. Country in which the acquired entity will have presence: Indonesia